GE Introduces Discovery LS

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WAUKESHA, Wisconsin-GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

WAUKESHA, Wisconsin—GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

The Discovery LS generates high-quality PET and CT images of a patient in a single 30-minute examination. Two image data sets are registered and fused to form a single image.

The Discovery LS is currently installed for clinical use at University Hospital, Zurich, Switzerland; Johns Hopkins Medical Institutions; and Rambam Medical Center, Haifa, Israel. GE forecasts that 30 systems will be installed worldwide by the end of this year and more than 500 in the next 3 years.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
Related Content